@basquiera

Médica Hematóloga. Hospital Privado Universitario de Cordoba. IUCBC. @SAHematologia #BMT #CART #quality #cellulartherapy

hospitalprivado.com.ar/
Joined April 2019
  • Tweets1.2K
  • Following344
  • Followers529
42Media
Ana Lisa Basquiera retweeted
Haematologica@HaematologicaOct 21
Relapse is a challenge after allogeneic transplantation in FLT3-ITD AML. A large German registry study examines FLT3 inhibitor maintenance after transplant, highlighting real-world outcomes with sorafenib and other FLT3 inhibitors. doi.org/10.3324/haematol.202…
11
1
50
2,513
Ana Lisa Basquiera retweeted
Nico Gagelmann
@NicoGagelmannOct 13
Really excited to share the first comprehensive study of germline DDX41 in MDS undergoing transplantation in @BloodPortfolio . Grateful to Coleman Lindsley, germline brain Chris Reilly @DanaFarber and whole team from @CIBMTR 🙏❤️ ashpublications.org/blood/ar…

Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse...

Key Points. Germline DDX41 is independently associated with lower relapse and improved DFS in MDS undergoing allogeneic transplantation.No excess non-relap

ashpublications.org
5
24
1
100
8,354
Ana Lisa Basquiera retweeted
Andres Gomez
@GomezDLeonMDOct 12
Teclistamab densitization of donor-specific antibodies in aplastic anemia before haploHCT Spoiler alert: it works, and yes, lower doses were used 😉 Our paper is out in Early View | @Haematologica haematologica.org/newsletter…
1
18
1
73
3,470
Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma ashpublications.org/blood/ar…

Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma

Key Points. Soluble BCMA integrates serologic, marrow, and imaging tumor burden metrics in newly diagnosed myeloma.Baseline soluble BCMA identifies aggress

ashpublications.org
1
1
102
This study found that ≥10% FEV1 decline affected ~48% of #alloHSCT recipients and was the strongest predictor of post-transplant mortality. Mortality risk remained elevated even after FEV1 recovery. Read: astctjournal.org/article/S26…
4
7
643
Ana Lisa Basquiera retweeted
Mostafa Faisal@MostafaFaisal14Oct 9
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study ashpublications.org/blood/ar…

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated...

Key PointsNPM1low defines a distinct subset of NPM1mut AML enriched in secondary AML features and linked to inferior survival despite NPM1 mutation.Mutatio

ashpublications.org
1
4
10
922
Ana Lisa Basquiera retweeted
Wellington Fernandes@wellingtonhematOct 8
Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin America: insights from a large multinational cohort - The Lancet Regional Health – Americas thelancet.com/journals/lanam… 🇦🇷🇧🇷🇨🇱

Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin...

Survival of adults with ALL in Latin America has improved compared with historical reports, but substantial disparities persist between public and private settings. Our findings support prioritizing...

thelancet.com
8
1
26
1,294
Ana Lisa Basquiera retweeted
Raul Cordoba, MD, PhD@DrRaulCordobaOct 3
Proud to see @AnnaSureda5 on stage at #ISHL 2026 in Cologne, Germany 🇩🇪. The only Spaniard 🇪🇸 presenting in the International Symposium on Hodgkin Lymphoma #lymsm @sehh_es @geltamo
6
1
38
1,009
Ana Lisa Basquiera retweeted
ASTCT
@ASTCTSep 27
Join ASTCT on Oct. 15 for an in-depth discussion on transplant considerations and emerging approaches for older patients with TP53-mutated disease. Register:
1
2
456
Ana Lisa Basquiera retweeted
ASTCT
@ASTCTSep 22
📊 New Infographic on ASTCT Nucleus: Geriatric assessment can help identify patient vulnerabilities, predict outcomes, and guide personalized care for older adults undergoing transplantation and cellular therapy. Explore key insights, implementation strategies, and expert recommendations for integrating geriatric assessment into clinical practice. 🔗 astct.org/Nucleus/Article/in…
2
4
460
Ana Lisa Basquiera retweeted
INCUCAI
@incucaioficialSep 22
Laura donó células para salvar la vida de otra persona en el mundo 🌎 El Día Mundial del Donante de Médula Ósea se celebra cada año con el objetivo de agradecer a los donantes. Es una oportunidad para crear conciencia sobre la importancia de inscribirse en el Registro Nacional de Donantes de Células Progenitoras Hematopoyéticas (CPH). El Registro argentino forma parte de la World Marrow Donor Association (WMDA), una red conformada por los Registros de 63 países. Así, una persona que necesita un trasplante puede encontrar un donante compatible sin importar dónde se encuentre.  ¿Querés ser parte de la red? El primer paso es inscribirse 💛 Si tenés entre 18 y 40 años y gozás de buena salud, podés hacerlo donando sangre (tenés que pesar más de 50kg) o con un hisopado bucal ✅ Encontrá los centros habilitados 👉🏻 argentina.gob.ar/salud/mapam… #DonáCélulas #WMDD
11
2
15
1,033
Ana Lisa Basquiera retweeted
NEJM
@NEJMSep 23
Yi Lin, MD, PhD, describes the science behind a phase 1 study of anitocabtagene autoleucel, a CAR T cell that deploys a CAR with a novel synthetic antigen-binding domain, in patients with multiple myeloma. Learn more about the science behind the study in the editorial “Anito-cel for Multiple Myeloma”: nej.md/4hF5Gxj
A detailed scientific diagram from "Science behind the Study: Anito-cel for Multiple Myeloma" that shows chimeric antigen receptor (CAR) design.

ALT A detailed scientific diagram from "Science behind the Study: Anito-cel for Multiple Myeloma" that shows chimeric antigen receptor (CAR) design.

1
49
147
22,657
Proud to share our latest publication from the Argentine GATMO-TC network @SAHematologia on allogeneic transplantation for Chronic Myeloid Leukemia in the TKI era. 🇦🇷 rdcu.be/BqEwdfFxiHWa @SpringerNature #CML #AlloHCT #BloodCancer #BMT #Hematology
2
14
495
Ana Lisa Basquiera retweeted
NEJM
@NEJMSep 16
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results: nej.md/4dBfwOk Editorial: Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia nej.md/3UWmKWP
A graph from an Original Article published in the New England Journal of Medicine article titled "Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia." The graph shows event-free survival. The trial name, AIEOP-BFM ALL 2017, is in parentheses after the title. The NEJM identity sits at the bottom.

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia." The graph shows event-free survival. The trial name, AIEOP-BFM ALL 2017, is in parentheses after the title. The NEJM identity sits at the bottom.

1
53
9
164
30,926
Ana Lisa Basquiera retweeted
ASTCT
@ASTCTSep 16
The latest ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy has been published in Transplantation and Cellular Therapy, providing a standardized framework for grading toxicities associated with immune effector cell therapies. ,The guidance maintains and clarifies grading for CRS and ICANS, introduces modified ICE (M-ICE) for children and patients with developmental delays, and addresses emerging toxicities including hematotoxicity, IEC-HS and non-ICANS neurotoxicities. 📖 Read the full guideline: ow.ly/59na50ZOqrR @ASTCT_Journal
13
1
19
3,140
Ana Lisa Basquiera retweeted
ASH
@ASH_hematologySep 16
New clinical guidelines for iron deficiency from ASH aim to help identify cases that may otherwise go undiagnosed. Updated ferritin thresholds support earlier, more accurate diagnosis. Learn more: ow.ly/xOeg50ZOjwB @BloodPortfolio
9
231
24
586
107,045
Ana Lisa Basquiera retweeted
Uriel Suárez
@UsuarezMDSep 16
American Society of Hematology 2026 guidelines for diagnosis of iron deficiency ashpublications.org/bloodadv…

American Society of Hematology 2026 guidelines for diagnosis of iron deficiency

Background: Iron deficiency is the most common micronutrient deficiency, and when untreated progresses to anemia. Existing guidance on the diagnostic crite

ashpublications.org
1
62
172
11,166
Ana Lisa Basquiera retweeted
INCUCAI
@incucaioficialSep 11
El Dr. Richard Malan es el nuevo presidente del INCUCAI. Médico especialista en Clínica Médica, Hemoterapia e Inmunohematología y Gestión de Servicios de Salud, Malan se desempeñaba hasta el momento como vicepresidente de la institución. La Dra. Gabriela Hidalgo, quien ocupaba el cargo de directora, estará a cargo de la vicepresidencia. argentina.gob.ar/noticias/el…
3
9
3
21
1,966
🗓️ SAVE THE DATE | Próximo Ateneo SAH de Septiembre: "Síndrome antifosfolipídico, el gran simulador". Actividad conjunta con las Jornadas Cuyanas de Hematología 2026. 📅 Viernes 25/9 - 17:00 hs 💻 Modalidad Virtual #Hematología #SAH #EducaciónMédica #Salud
1
3
6
197
Ana Lisa Basquiera retweeted
Mostafa Faisal@MostafaFaisal14Sep 12
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial - The Lancet Haematology share.google/LbwHdAZLV3tzgtT…

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE...

Epcoritamab plus rituximab–lenalidomide showed high activity in first-line treatment for follicular lymphoma, with 95% of patients having a response over 3 years of follow-up, supporting this...

thelancet.com
1
10
26
1,963
Load more